Skip to main content
. 2021 Apr 13;7(2):e18819. doi: 10.2196/18819

Table 2.

Baseline characteristics of the mobile health intervention study participants.

Characteristic Combined groups (N=54) Intervention group: tech support (n=18) Intervention group: tech support+health coaching (n=18) Waitlist control group (n=18)
Sociodemographic characteristics

Age (years), mean (SD) 69.6 (4.8) 69.6 (4.5) 69.1 (4.0) 70.2 (5.9)

BMI, mean (SD) 30.1 (5.7) 30.2 (6.0) 29.8 (4.8) 30.4 (6.5)

BMI, n (%)


Normal weight 10 (18) 4 (22) 2 (11) 4 (22)


Overweight 21 (39) 6 (33) 9 (50) 6 (33)


Obese 23 (43) 8 (44) 7 (39) 8 (44)

Male, n (%) 24 (44) 10 (56) 6 (33) 8 (44)

Ethnicity, n (%)


Hispanic 13 (24) 5 (28) 4 (22) 4 (22)


Non-Hispanic 41 (76) 13 (72) 14 (78) 14 (78)

Race, n (%)


Non-White 4 (7) 1 (6) 2 (11) 1 (6)


White 50 (93) 17 (94) 16 (89) 17 (94)

College degree, n (%) 31 (57) 11 (61) 11 (61) 9 (50)

Household income, n (%)


<US $50,000 19 (35) 7 (39) 8 (44) 4 (22)


≥US $50,000 32 (59) 10 (56) 9 (50) 13 (72)


Missing or refused 3 (6) 1 (6) 1 (6) 1 (6)
Health and physical functioning

Ever smoker, n (%)a 24 (44) 8 (44) 7 (39) 9 (50)

General health status, n (%)


Fair or poor 8 (15) 4 (22) 2 (11) 2 (11)


Good 22 (41) 9 (50) 6 (33) 7 (39)


Very good or excellent 24 (44) 5 (28) 10 (56) 9 (50)

Number of comorbidities, n (%)


0-1; does not limit activities 27 (50) 10 (56) 8 (44) 9 (50)


1-2; limits activities 16 (30) 6 (33) 5 (28) 5 (28)


≥3; limits activities 11 (20) 2 (11) 5 (28) 4 (22)

Self-reported physical function, mean (SD)




Raw score (0-100) 73.7 (20.7) 68.1 (22.4) 77.5 (15.4) 75.6 (23.2)


T-scoreb 47.5 (7.9) 45.3 (8.6) 48.9 (5.9) 48.2 (8.9)

Short Physical Performance Battery (0-12), mean (SD) 10.7 (1.6) 10.4 (2.2) 11.1 (0.9) 10.7 (1.5)
Clinical characteristics

Cancer type, n (%)


Breast 21 (39) 7 (39) 9 (50) 5 (28)


Prostate 16 (30) 7 (39) 3 (17) 6 (33)


Otherc 17 (31) 4 (22) 6 (33) 7 (39)

Stage at diagnosisd, n (%)


Local 40 (75) 14 (78) 14 (78) 12 (71)


Regional 13 (25) 4 (22) 4 (22) 5 (29)

Treatment receivede, n (%)


Surgery 42 (78) 13 (72) 13 (72) 14 (78)


Chemotherapy 10 (18) 3 (17) 3 (17) 4 (22)


Radiation 30 (56) 12 (67) 10 (56) 8 (44)


Hormone therapy 12 (22) 2 (11) 6 (33) 4 (22)

Time since diagnosis (years), mean (SD) 4.4 (1.6) 4.3 (1.4) 4.2 (1.9) 4.6 (1.4)
Other characteristics

Comfort level with using smartphone, n (%)


Very or extremely comfortable 38 (70) 11 (61) 13 (72) 14 (78)


Slightly or not comfortable 16 (30) 7 (39) 5 (28) 4 (22)

activPAL data, mean (SD)


Number of valid wear daysf 6.7 (0.7) 6.6 (1.0) 6.8 (0.4) 6.7 (0.5)


Average awake hours 14.5 (1.0) 14.1 (1.1) 14.6 (0.6) 14.6 (0.9)

aOnly 1 participant was currently smoking at baseline.

bT-scores represent a linear transformation, normed to the US population, with a mean of 50 (SD 10).

cOther cancers include bladder, cervical, colon, endometrium, kidney, lymphoma, or melanoma cancers.

dStage at diagnosis is missing for 1 participant.

ePercentages do not add up to 100% because participants may have had more than 1 type of treatment.

fUp to the first 7 days of 10 hours or more of awake/wear time were included in the analyses; additional days of wear beyond the first 7 days were excluded.